Inhibition of Sympathetic Vasoconstriction Is a Major Principle of Vasodilation by Nitric Oxide In Vivo

Johannes Zanzinger, Jürgen Czachurski, Horst Seller

Abstract The objective of this study was to determine whether vasodilator effects of nitric oxide (NO) can be explained by the inhibition of vasoconstriction caused by peripheral sympathetic nerve activity (SNA) in vivo. For this purpose, we studied the effects of systemic inhibition of NO synthesis during experimental variation of SNA in anesthetized cats. Intravenous infusion of N\textsuperscript{\textregistered}-nitro-L-arginine methyl ester (L-NAME, 10 mg/kg) in baroreceptor-intact animals (n=6) caused increases in mean arterial blood pressure (MAP) from 105.8±3.4 to 192.0±4.3 mm Hg that were associated with slight decreases in preganglionic SNA recorded from the white ramus of the third thoracic segment. Higher SNA was observed in completely baroreceptor-denervated cats (n=10) than in the intact cats, but no changes in nerve activity occurred after the subsequent administration of L-NAME. In contrast, MAP increased from 123.3±4.0 to 245.8±5.1 mm Hg. In baroreceptor-denervated cats, reversible suppression of peripheral SNA produced by cooling of the ventral surface of the rostral ventrolateral medulla oblongata (RVLM) caused significant hypotension (61.1±2.6 mm Hg) and almost completely reversed the hypertension caused by L-NAME (76.0±3.7 mm Hg). Intravenous administration of the \(\alpha\)-adrenergic receptor antagonist prazosin after L-NAME reduced MAP to a similar extent. In contrast, hypertension induced by angiotensin II could not be reversed by RVLM cooling. Thepressor effects of intravenously administered noradrenaline during RVLM cooling were markedly potentiated by L-NAME and attenuated by the NO-donor compound S-nitroso-N-acetylpenicillamine (SNAP). These results demonstrate that inhibition of peripheral sympathetic vasoconstriction is an important mechanism of vasodilation by NO in vivo and suggest that the vascular effects of NO may be very closely linked to the regulation of cardiovascular functions by the central nervous system. (Circ Res. 1994;75:1073-1077.)

Key Words: nitric oxide • neurogenic vasoconstriction • sympathetic nerve activity • \(N\textsuperscript{\textregistered}\)-nitro-L-arginine methyl ester • cats

The vascular release of nitric oxide (NO), which is probably identical with the endothelium-derived relaxing factor (EDRF),\textsuperscript{1,2} causes tonic reduction of smooth muscle tone in vivo.\textsuperscript{3} Its synthesis is inhibited by guanidino-substituted L-arginine analogues, such as \(N\textsuperscript{\textregistered}\)-nitro-L-arginine (L-NNA), \(N\textsuperscript{\textregistered}\)-nitro-L-arginine methyl ester (L-NAME), or \(N\textsuperscript{\textregistered}\)-monomethyl-L-arginine.\textsuperscript{4} Systemic administration of these inhibitors in anesthetized and conscious animals causes marked blood pressure increases and impairment of regional circulation.\textsuperscript{5-8} Apart from the direct actions of NO on vascular smooth muscle, additional roles for NO in the central nervous regulation of cardiovascular functions have been proposed. Several groups have shown that systemic inhibition of the synthesis of NO caused changes in peripheral sympathetic nerve activity (SNA) in rats\textsuperscript{9-11} and in rabbits,\textsuperscript{12} effects that were, however, influenced by concomitant changes in the baroreflex control of SNA. At sympathetic nerve endings, another important effect of NO may occur. Recent in vitro studies revealed inhibitory effects of NO and potentiating effects of L-NNA\textsuperscript{13} or L-NAME\textsuperscript{14,15} on the vasoconstrictor responses to electrical sympathetic nerve stimulation, suggesting a peripheral modulation of the sympathetic vasoconstriction by NO that is independent of the degree of central SNA. Finally, the involvement of putative nitroxidergic peripheral vascular nerves has been recently discussed, since in pentobarbital-anesthetized dogs pharmacological ganglionic blockade prevented hypertension induced by inhibition of NO synthesis, whereas the broad spectrum \(\alpha\)-adrenergic antagonist phentolamine was much less effective.\textsuperscript{16}

The aim of the present study was to test the hypothesis that the vasodilator actions of vascular NO in vivo can be explained, at least in part, by peripheral inhibition of sympathetic vasoconstriction. For this purpose, chloralose-anesthetized cats were prepared for reversible cooling of the rostral ventrolateral medulla oblongata (RVLM), the area within the brainstem that controls central sympathetic outflow.\textsuperscript{17} After complete baroreceptor denervation, we studied the effects of a substantial reduction in central SNA by RVLM cooling before and after inhibition of NO synthesis by L-NAME and compared it with the effects of angiotensin II and \(\alpha\)-receptor blockade by prazosin. In addition, dose-response curves for intravenously infused noradrenaline during RVLM cooling were performed before and after the administration of L-NAME as well as after the administration of the spontaneously NO-releasing compound S-nitroso-N-acetylpenicillamine (SNAP).

Materials and Methods

Experiments were performed on cats (2.5 to 4.5 kg body weight) that were initially sedated by ketamine (10 mg/kg IM) and anesthetized by \(\alpha\)-chloralose (40 to 50 mg/kg IV). Addi-
tional doses of α-chloralose were administered when required. Catheters were placed into a femoral vein and artery for infusion of drugs and for measurement of arterial blood pressure via a pressure transducer (Statham PD23ID), respectively. The cats were paralyzed by 0.6 mg pancuronium bromide and artificially ventilated via a tracheal cannula. Rectal temperature was maintained at 38.0°C to 38.5°C by a thermostatically controlled infrared lamp.

For complete baroreceptor denervation, the carotid sinus and vagoaortic nerves were cut. The denervation was verified by the absence of changes in SNA during blood pressure increases caused by 1 μg/kg IV noradrenaline. The left white ramus (n=16) of the third thoracic segment (WR-T3) was exposed retropleurally after removal of the head and dorsal portion of the second and third ribs. The renal nerve (n=4) was exposed retroperitoneally. To minimize thoracic movements due to ventilation, a procedure producing a pneumothorax was performed. All nerves were kept in a pool of warm paraffin oil and placed on bipolar electrodes for SNA recording. Neural signals were amplified and filtered (model AM 502 amplifier; bandwidth, 10 Hz to 10 kHz; Tektronix). WR-T3 activity was recorded as counted impulses at intervals of 0.3 second and is expressed in the figures as impulses per second, whereas renal nerve activity is presented as a resistance-capacity-integrated signal. For SNA inhibition by cooling, the ventral surface of the RVLM was exposed. In the cat, the RVLM projects onto the ventral surface =1 mm rostral to the most cranial rootlet of the 12th cranial nerve and 4 mm lateral to the midline. Cooling of the RVLM was performed by using a hollow metal thermode shaped to closely contact both sides of the RVLM simultaneously. The temperature of the inner surface of the thermode was continuously monitored and during control conditions was kept at 38.5°C by perfusion of thermostatically controlled warm water. For cooling the RVLM to 5.0°C to 3.0°C, the perfusion of the thermode was switched to cold ethanol provided by a cryostat. The desired temperature level could be maintained by manually adjusting the flow through a clamp. To prevent irreversible damage of neuronal structures, the duration of cooling was limited to 4 to 8 minutes.

L-NAME, prazosin (Sigma), and SNAP (Schwarz Pharma) were dissolved in Ringer’s solution. Noradrenaline (norepinephrine [Aterenol], Hoechst) and angiotensin II (Hypertensin, Ciba-Geigy) were obtained as ready-for-use solutions. All drugs were further diluted in Ringer’s solution and administered by short-term infusion at the doses stated in “Results.” Measurements were taken when steady-state responses were reached.

Data were analyzed by ANOVA for repeated measurements, and comparison of means was carried out by the Tukey method. For comparison of means between groups of different animals (intact and denervated), t tests with the Bonferroni correction were used (SAS Institute). Differences of \( P < 0.05 \) were considered to be significant. Values are reported as mean±SEM.

**Results**

**Effects of Systemic NO Blockade in Intact and Baroreceptor-Denervated Cats**

Changes in mean arterial pressure (MAP) and preganglionic SNA (WR-T3) in response to systemic inhibition of NO synthesis by intravenous infusion of L-NAME (10 mg/kg) in intact (n=6) and baroreceptor-denervated (n=10) cats are shown in Fig 1. In intact cats, L-NAME increased MAP, leading to decreases in SNA, which, however, did not reach statistical significance. In baroreceptor-denervated cats (n=10), mean baseline SNA and MAP were higher, but the administration of L-NAME did not significantly alter SNA during the whole study period in these animals. However, the pressor responses to L-NAME were significantly enhanced when compared with the intact group (\( P < 0.01 \), t test). When baroreceptor denervation was performed in intact animals after the L-NAME treatment (n=4), MAP and SNA values appeared that were similar to those observed in animals that had been denervated before the administration of L-NAME (data not shown). This unmasking of pressor responses to L-NAME after removal of the baroreflex inhibition of SNA is shown in Fig 2. This figure also shows the closely parallel courses of preganglionic SNA (WR-T3) and postganglionic SNA (renal nerve), which were recorded simultaneously in four experiments. Neither RVLM cooling nor any drug used in the present study altered the relation between these nerve activities.

**Effects of RVLM Cooling**

The effects of experimental variation of central sympathetic tone on the peripheral vasoconstrictor effects of L-NAME and angiotensin II were studied in baroreceptor-denervated cats (n=10). The obligatory role of the presence of SNA for the pressor effects of NO blockade is shown in a representative tracing in Fig 3. Cooling of the RVLM almost completely reversed the hypertension induced by L-NAME. This was likewise achieved by α1-adrenergic receptor blockade during NO blockade (Fig 3B). Additional depressor effects of RVLM cooling thereafter may be related to reductions in cardiac output caused by bradycardia and the lack of inotropic sympathetic effects. Fig 4 summarizes the depressor effects of effective inhibition of peripheral SNA by RVLM cooling. RVLM cooling reduced MAP...
in L-NAME-treated denervated cats from 245.8±4.9 to 76.0±3.7 mm Hg, which represents a mean difference of 169.8 mm Hg. In contrast, after induction of hypertension by angiotensin II (1.5 μg/kg per minute), RVLM cooling caused only a mean decrease of 63.7 mm Hg, which is similar to the hypotensive responses during control conditions. As shown by the concomitant changes in preganglionic SNA in Fig 2, RVLM cooling effectively suppressed SNA irrespective of the different infusions. At the concentrations used in the present study, none of the applied substances significantly altered central sympathetic tone.

**NO Dependence of the Responses to Intravenous Noradrenaline**

Presynaptic or postsynaptic mechanisms or both could mediate peripheral inhibition of sympathetic vasoconstriction. The involvement of postsynaptic mechanisms is shown in Fig 5. We assessed dose-response relations for intravenously infused noradrenaline (upper panel) in baroreceptor-denervated cats (n=10) during RVLM cooling to suppress the neural constrictor tone. The average preganglionic SNA throughout these measurements was 48.5±9 impulses per second. The vascular sensitivity to the pressor effects of noradrenaline was significantly enhanced by L-NAME. The opposite effect, ie, marked attenuation of the pressor responses to noradrenaline, was observed when dose-response relations were obtained after the administration of the spontaneously NO-releasing compound SNAP (60 μg/kg) in L-NAME-treated cats (n=5). Exogenous NO supply decreased the responses to noradrenaline in these animals more than 10-fold. In the lower panel of Fig 5, similar dose-response relations for angiotensin II, obtained from four cats, are depicted. The modulation of the dose-response relation for angiotensin II by the absence (L-NAME) or presence
Similar results have been obtained in rats. The present study has revealed peripheral inhibitory effects of NO on sympathetic vasoconstriction that are independent of the central sympathetic tone, since baseline SNA was not altered by L-NAME in the baroreceptor-denervated cats used for the RVLM cooling experiments. The effects of \( \alpha \)-adrenergic receptor blockade support this view. Furthermore, previous in vitro studies revealed an attenuation of the constrictor effects of electrical sympathetic nerve stimulation by endothelial NO, which is in line with our observations.

By use of pharmacologic ganglionic blockade, similar reductions of the pressor responses to NO blockade have been recently demonstrated in dogs; these reductions were interpreted by this group as a result of inhibition of putative nitroxidergic nerves mediating tonic relaxation, since phentolamine was much less effective. In another study on rats, hexamethonium failed to reverse the rather small hypertensive effects (+22 mm Hg), which were evoked by L-NAME in these animals, but in accordance with our findings (Fig 5), marked potentiation of pressor responses to phenylephrine by L-NAME were detected, whereas increases in pressor responses to angiotensin II after the administration of L-NAME were much smaller. Our experiments show that transient SNA inhibition is associated with a reversible and nearly complete disappearance of the pressor effects of L-NAME, suggesting that NO directly inhibits sympathetic vasoconstriction. The relation between preganglionic (WR-T3) and postganglionic (renal nerve) SNA, which was recorded simultaneously in four experiments (Fig 2), was neither affected by NO blockade nor by any other treatment. Significant effects of L-NAME on ganglionic transmission can therefore be ruled out. The observed effects of NO blockade are thus probably related to direct actions of NO at the nerve endings on smooth muscle cells. The origin of such adventitial NO remains to be determined. However, endothelial NO probably can reach the adventitial side at least in resistance vessels. Furthermore, it is possible that neuronally released NO may contribute to this effect, as recently suggested by Toda et al. This hypothesis has been supported by histocelchemical studies in the dog, revealing NO synthase immunoreactive nerve fibers in the adventitia of different vessels.

It has been shown in other species that systemic inhibition of NO synthesis can produce increases in baseline SNA, especially when high doses of the L-arginine analogues are used. Therefore, it is possible that NO has a dual function in the sympathetic nervous system in vivo, comprising both a reduction of central sympathetic tone and peripheral inhibition of its constrictor effects. There are studies that support this hypothesis. In rats chronically treated with L-NAME compared with control rats, much greater decreases in arterial blood pressure occurred after ganglionic blockade, but acute administration of L-NAME induced a potentiation of sympathetically vasoconstriction evoked by electrical nerve stimulation in pithed rats also.

Additional muscarinic blocking activity, which potentially could have produced side effects, has been reported for L-NAME. In cats, however, no differences exist between the effects of L-NNA and L-NAME. Furthermore, in all experiments on baroreceptor-dener-
vated cats (vagotomy), subsequent muscarinic blockade would not have been relevant.

Both presynaptic and postsynaptic mechanisms could account for the observed phenomenon. The leftward shift by L-NAME of the dose-response relations for noradrenaline in the absence of significant SNA and the analogous rightward shift caused by exogenous NO (Fig 5) provide evidence that postsynaptic mechanisms may be important. This evidence is supported by in vitro studies in which L-NAME did not alter noradrenaline release from sympathetic nerve endings.14 Interestingly, the endothelium was a prerequisite for the potentiation of vasoconstrictor effects of noradrenaline by L-NAME.13,15,16 This study supports the hypothesis that the autonomic nervous system plays a major role in the L-NAME-induced hyper-tension in conscious rats.17,18

Acknowledgment

This study was supported by the German Research Foundation (DFG) within the SFB 320.

References


Inhibition of sympathetic vasoconstriction is a major principle of vasodilation by nitric oxide in vivo.

J Zanzinger, J Czachurski and H Seller

_Circ Res._ 1994;75:1073-1077
doi: 10.1161/01.RES.75.6.1073

_Circulation Research_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1994 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/75/6/1073

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation Research_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation Research_ is online at:
http://circres.ahajournals.org/subscriptions/